AbbVie Reports the CHMP’s Positive Opinion of Elahere (Mirvetuximab Soravtansine) to Treat Ovarian Cancer
Shots:
- The CHMP has granted positive opinion to Elahere for treating FRα+, Pt-resistant & high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults who have received 1 to 3 prior therapies. The decision is anticipated in Q4’24, with other reviews underway
- The opinion was based on P-III (MIRASOL) study assessing Elahere vs CT in 453 ovarian cancer patients who had received 1-3 lines of prior treatments
- Study showed improved OS with mOS of 16.46mos. vs 12.75mos., a 33% reduction in risk of death, improved PFS with a 35% reduction in risk of tumor progression or death with an mPFS of 5.62mos. vs 3.98mos. and ORR of 42.3% (incl. 12 CRs) vs 15.9% (with no CRs)
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie Reports the P-II (PICCOLO) Study Data of Elahere (Mirvetuximab Soravtansine) for Treating Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
